{"id":"W4379284114","doi":"10.1200/jco.2023.41.16_suppl.tps1123","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Fulvestrant; Tolerability; Regimen; Internal medicine; Everolimus; Oncology; Pharmacology; Cancer; Adverse effect; Breast cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002690006,0.0006999891,0.004469831,0.0006541173,0.0001037417,0.00002354677,0.0005486154,0.000421659,0.0002252554],"category_scores_gemma":[0.001521486,0.0004740622,0.0004336855,0.002119811,0.0009520731,0.0007253339,0.000168948,0.002346505,0.0000157628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000989487,"about_ca_system_score_gemma":0.003329701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007017375,"about_ca_topic_score_gemma":0.001434994,"domain_scores_codex":[0.9900498,0.001808534,0.005019305,0.0008010998,0.00143872,0.0008824929],"domain_scores_gemma":[0.9881695,0.003801315,0.004379179,0.0005303588,0.002358935,0.0007607125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4886294,0.03918824,0.04670381,0.0002097196,0.003560319,0.005341483,0.005423759,0.002351508,0.0008805424,0.00001545006,0.0007462713,0.4069495],"study_design_scores_gemma":[0.2649194,0.1439876,0.5746338,0.001826283,0.001391601,0.0007204055,0.009034947,0.000233644,0.0003550065,0.0001335635,0.00211083,0.0006529093],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933748,0.0003004527,0.0003033337,0.002750302,0.0007460605,0.002101949,0.0001908918,0.00006259278,0.0001696602],"genre_scores_gemma":[0.9935795,0.001502333,0.003273676,0.0008081828,0.0003649432,0.0001269669,0.0000368345,0.0001296251,0.000177906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.52793,"threshold_uncertainty_score":0.9999551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04563171507472753,"score_gpt":0.4278713048804936,"score_spread":0.3822395898057661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}